efficacy. These findings provide a framework for rational bsAb design and underscore their promise as next-generation immunotherapeutics capable of broad and durable protection against diverse ebolaviruses.
Share your take
Add a clinician perspective alongside expert commentary.
Zhou et al. (2026) studied this question.